EVA DE
LAGO FEMIA
Profesora titular de universidad
JOSÉ JAVIER
FERNÁNDEZ RUIZ
Catedrático de universidad
Publicaciones en las que colabora con JOSÉ JAVIER FERNÁNDEZ RUIZ (41)
2024
-
Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice
Biomedicine and Pharmacotherapy, Vol. 174
2023
-
Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice
Journal of neuroinflammation, Vol. 20, Núm. 1, pp. 108
2022
-
New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Biomolecules, Vol. 12, Núm. 9
2021
-
Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis
International Journal of Molecular Sciences, Vol. 22, Núm. 22
-
Chapter 2: Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System
RSC Drug Discovery Series (Royal Society of Chemistry), pp. 10-47
-
Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis
Brain Pathology, Vol. 31, Núm. 6
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
-
Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis
British Journal of Pharmacology
-
Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis
British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387
2020
-
Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment
Scientific Reports, Vol. 10, Núm. 1
-
Pharmacokinetics of sativex® in dogs: Towards a potential cannabinoid-based therapy for canine disorders
Biomolecules, Vol. 10, Núm. 2
2019
-
Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
British Journal of Pharmacology, Vol. 176, Núm. 10, pp. 1585-1600
2018
-
Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 19, Núm. 5-6, pp. 377-386
-
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
Biochemical Pharmacology, Vol. 157, pp. 217-226
2017
-
Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis
DMM Disease Models and Mechanisms, Vol. 10, Núm. 5, pp. 551-558
2015
-
A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis
British Journal of Pharmacology, Vol. 172, Núm. 14, pp. 3579-3595
-
Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders
Journal of Neuroimmune Pharmacology, Vol. 10, Núm. 2, pp. 233-244
-
Endocannabinoids and amyotrophic lateral sclerosis
Cannabinoids in Neurologic and Mental Disease (Elsevier Inc.), pp. 99-123
-
The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors
Multiple Sclerosis and Related Disorders, Vol. 4, Núm. 6, pp. 505-511
2014
-
Changes in endocannabinoid receptors and enzymes in the spinal cord of sod1g93a transgenic mice and evaluation of a sativex®-like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis
CNS Neuroscience and Therapeutics, Vol. 20, Núm. 9, pp. 809-815